Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Open Access
- 1 September 2012
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 12 (5) , 410-416
Abstract
Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.Keywords
This publication has 61 references indexed in Scilit:
- Heart repair by reprogramming non-myocytes with cardiac transcription factorsNature, 2012
- In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytesNature, 2012
- BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA ExpressionMolecular Therapy, 2012
- Direct lineage conversions: unnatural but useful?Nature Biotechnology, 2011
- Engineering Biomaterial Systems to Enhance Viral Vector Gene DeliveryMolecular Therapy, 2011
- Urokinase-Targeted Fusion by Oncolytic Sendai Virus Eradicates Orthotopic Glioblastomas by Pronounced Synergy With Interferon-β GeneMolecular Therapy, 2010
- Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSVVaccine, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Generation of germline-competent induced pluripotent stem cellsNature, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006